Tadafil: Tadalafil Brand by Ajanta Pharma

Tadafil Product Facts at a Glance

Current Indian pharmacy records provide a clear product identity for Tadafil 20 mg. The listing identifies tadalafil 20 mg as the composition, shows a strip of four tablets and names Ajanta Pharma Limited as marketer.

A separate current listing documents Tadafil 10 mg with tadalafil 10 mg, also in a four-tablet strip and also with Ajanta Pharma Limited as marketer. These records provide strong current evidence for the Indian Tadafil-Ajanta commercial relationship without requiring a stronger manufacturer claim for the exact packs.

Tadafil 20 mg Is the Core Product for This Page

Tadafil 20 mg is currently documented in the Indian market as a tadalafil 20 mg tablet associated with Ajanta Pharma. That directly satisfies the primary product intent behind searches for Tadafil 20 and Tadafil tadalafil.

The 20 mg number identifies the amount of tadalafil in the tablet rather than a universal dose recommendation. Product strength and individualized tadalafil dosing are different questions.

General clinical dose frameworks belong on the tadalafil dosage guide rather than being rebuilt around the Tadafil brand.

Tadafil 10 mg Is Also Currently Documented

Current Indian market data also identifies Tadafil 10 mg as a tadalafil-only tablet marketed by Ajanta Pharma Limited. Like the 20 mg presentation, the current listing shows a four-tablet strip.

This means the brand should not be described as though 20 mg were the only Tadafil strength in the Indian market evidence. At the same time, the page does not construct a larger Indian strength range without equally current Tadafil-specific records.

The appropriate conclusion is therefore narrow and source-based: 10 mg and 20 mg are currently documented Indian Ajanta-associated Tadafil presentations.

Tadafil, Tadalafil and Ajanta Pharma Are Different Entity Levels

Tadafil is the commercial product name, tadalafil is the active pharmaceutical ingredient and Ajanta Pharma Limited is the company identified as marketer in current Indian Tadafil listings. Those three labels answer different questions about the medicine.

Tadalafil appears under many brands, and Ajanta itself has broader generic and branded-generic operations beyond Tadafil. The Tadafil name therefore should not be used as a synonym for either tadalafil generally or every tadalafil product associated with Ajanta.

The broader company relationship is covered on the Ajanta Pharma tadalafil page.

Ajanta's Tadafil Marketer Role Should Not Be Automatically Rewritten as Manufacturer

Current Indian Tadafil 10 mg and 20 mg records specifically identify Ajanta Pharma Limited as marketer. That is sufficient to establish a direct current commercial relationship between Ajanta and those products.

Ajanta is independently documented as a tadalafil manufacturer in other jurisdictions. Current U.S. labeling identifies Ajanta Pharma Limited in India as manufacturer of generic tadalafil tablets in 2.5 mg, 5 mg, 10 mg and 20 mg strengths, but those are separate regulated products rather than proof of the manufacturing chain for every Indian Tadafil pack.

This page therefore preserves both facts without collapsing them: Ajanta is the current documented Indian Tadafil marketer and is separately a documented tadalafil manufacturer.

Ajanta Has Directly Documented Tadalafil Manufacturing Capability

Ajanta's tadalafil activity extends beyond the Indian Tadafil marketer records. Current U.S. DailyMed labeling for Ajanta's generic tadalafil identifies the products as manufactured by Ajanta Pharma Limited in India and documents 2.5 mg, 5 mg, 10 mg and 20 mg strengths.

Ajanta also states that it operates multiple manufacturing facilities in India and that its business includes branded generics in India and several international markets as well as generic medicines in the United States. These company facts explain how one pharmaceutical company can appear in different tadalafil product relationships across jurisdictions.

Company-wide manufacturing and market analysis belongs on Ajanta Pharma tadalafil; this page uses that context only to clarify the Tadafil entity.

Tadafil D Is Not the Same Product as Pure Tadafil

A similarly named product, Tadafil D, is currently documented with tadalafil 10 mg plus dapoxetine 30 mg. It is therefore a combination medicine and should not be merged into the pure-tadalafil Tadafil strength range.

The distinction is even clearer at the company level: the current Tadafil D 10 mg/30 mg listing identifies D D Pharmaceuticals as marketer rather than Ajanta Pharma. Similar naming therefore does not establish identical composition, company relationship or product identity.

For the Tadafil entity on this page, only single-ingredient tadalafil presentations are treated as core Tadafil products.

Why a Tadalafil-Dapoxetine Product Cannot Be Treated as Another Tadafil Strength

A combination product contains two pharmacologically active ingredients, so a label such as 10 mg/30 mg does not represent a larger or smaller dose of tadalafil alone. The two figures refer to tadalafil and dapoxetine separately.

Adding dapoxetine also introduces a second pharmacologic mechanism, additional adverse-effect considerations and additional drug-interaction questions. A pure tadalafil product and a tadalafil-plus-dapoxetine product therefore require different entity and safety treatment.

This is why Tadafil D remains outside the core Tadafil product fact and strength tables.

The Tadafil Name Can Refer to Different Products in Different Markets

Brand names can create additional confusion across jurisdictions. An official Philippine FDA package insert uses the Tadafil name for tadalafil 2.5 mg, 5 mg, 10 mg and 20 mg products but identifies Hetero Labs Limited in India as manufacturer and Camber Pharmaceuticals as importer and distributor.

That is a different documented company relationship from the current Indian Tadafil listings that identify Ajanta Pharma Limited as marketer. The shared brand word therefore cannot be used by itself to prove that products from two markets have the same manufacturer, applicant or commercial chain.

The exact country, strength, package information and company fields should always accompany the Tadafil name when regulatory identity matters.

How Tadafil Fits the Branded-Generic Tadalafil Market

The Indian Ajanta-associated Tadafil product can be described in market terms as a branded tadalafil product: an established active ingredient is presented under a commercial product name. This is distinct from using tadalafil as the nonproprietary drug name.

That market description does not automatically make Tadafil an FDA-approved generic of Cialis. U.S. generic status and therapeutic equivalence apply to specific FDA-approved drug products rather than to every foreign-market product sharing tadalafil and a familiar strength.

The regulatory distinction is covered more fully on the generic tadalafil page.

Tadafil and Cialis Share Tadalafil but Are Different Finished Products

Tadafil and Cialis can contain the same active drug and can overlap at nominal strengths such as 10 mg and 20 mg. Those similarities establish an ingredient-and-strength relationship rather than identity between the finished products.

Brand, marketer, manufacturer, formulation, regulatory application and bioequivalence evidence remain separate characteristics. Tadafil 20 therefore should not be described as Cialis simply because both products can contain tadalafil 20 mg.

The broader branded-versus-generic framework belongs on tadalafil vs Cialis rather than being duplicated here.

Tadafil Regulatory Identity Must Be Verified by Jurisdiction

Tadafil demonstrates why a product name cannot be separated from its country context. Current Indian records associate Tadafil 10 mg and 20 mg with Ajanta Pharma as marketer, while Philippine regulatory documentation uses the Tadafil name with a different documented manufacturer and distribution chain.

Likewise, Ajanta's U.S. tadalafil products are directly documented as manufactured by Ajanta but are regulated as separate generic tadalafil products rather than relying on the Indian Tadafil market listing. Each of these records is valid within its own product and jurisdiction context.

For that reason, approval, therapeutic equivalence and manufacturer identity should always be established for the exact Tadafil or tadalafil product being discussed.

Tadafil 20 mg Is a Product Strength, Not a Universal Dose Recommendation

The 20 mg in Tadafil 20 identifies the amount of tadalafil in the documented tablet. It does not mean that every person using tadalafil should receive 20 mg or that 20 mg is the appropriate regimen for every indication.

Tadalafil dosing depends on the clinical context, dosing schedule, interacting medicines, kidney and liver function and the authorized labeling for the specific product. Available strength and individualized dose selection are therefore separate concepts.

The wider dosing framework belongs on the tadalafil dosage page.

Pure Tadafil Uses Tadalafil's PDE5 Pharmacology

Pure Tadafil contains tadalafil, a phosphodiesterase type 5 inhibitor. PDE5 inhibition reduces degradation of cyclic GMP in tissues where nitric oxide-cGMP signaling is active.

That basic pharmacology comes from tadalafil rather than from the Tadafil brand name or the company marketing the product. Tadafil D differs because it adds dapoxetine as a second active drug.

The tadalafil pathway is covered in depth on how tadalafil works.

Pure Tadafil Shares Tadalafil's Active-Ingredient Safety Context

Because pure Tadafil contains tadalafil, major tadalafil contraindication and interaction principles are relevant to understanding the active drug. Important examples include potentially dangerous blood-pressure effects with nitrates and guanylate cyclase stimulators, alongside other medicine- and patient-specific considerations.

Exact product labeling still matters. A CIALIS label, an Ajanta U.S. generic label or the labeling for a Tadafil product in another jurisdiction should not automatically be presented as the authorized instructions for an Indian Tadafil pack.

Detailed active-ingredient safety belongs on tadalafil contraindications, tadalafil drug interactions and tadalafil side effects.

Tadafil Is Only One Part of Ajanta Pharma's Tadalafil Context

Ajanta Pharma operates branded-generic businesses across multiple international markets and a generic business in the United States. Its current company information also documents multiple manufacturing facilities in India.

Those company facts are relevant because they explain why Ajanta can appear as marketer of Tadafil in India and manufacturer of separately regulated generic tadalafil elsewhere. They do not need to be reproduced in full on a product-entity page.

The broader company and cross-market analysis belongs on the Ajanta Pharma tadalafil profile.

How to Verify a Tadafil Product

The Tadafil name should be checked together with strength, full active-ingredient list, pack information, marketer or manufacturer field and country. This is necessary because similar Tadafil names can identify different compositions and company relationships.

For the current Indian products discussed here, established pharmacy records support Ajanta Pharma marketer attribution for Tadafil 10 mg and 20 mg. Tadafil D is separately documented with tadalafil plus dapoxetine and a different marketer, while an official Philippine Tadafil record has another manufacturer.

Regulatory approval or therapeutic-equivalence claims require the appropriate national regulator and should not be inferred from the product name alone.

Common Misunderstandings About Tadafil

A common mistake is to assume that every product using the Tadafil name is the same medicine from the same company. Current evidence shows pure Indian Tadafil associated with Ajanta, Tadafil D with a different marketer and a separate Philippine Tadafil product with another documented manufacturer.

Another mistake is to call Ajanta the manufacturer of an exact Indian Tadafil pack merely because Ajanta manufactures tadalafil elsewhere. The current Indian source specifically establishes Ajanta as marketer, while manufacturing evidence must remain tied to the product for which it is documented.

Finally, tadalafil 20 mg content does not make Tadafil identical to Cialis or automatically establish FDA therapeutic equivalence.

Key Takeaways: Tadafil

Current Indian records document Tadafil 20 mg as tadalafil 20 mg in a four-tablet strip with Ajanta Pharma Limited identified as marketer. Tadafil 10 mg is also currently documented with tadalafil 10 mg, the same four-tablet pack format and the same Ajanta marketer relationship.

Tadafil D must remain outside the pure-tadalafil Tadafil entity because it contains tadalafil 10 mg plus dapoxetine 30 mg and is currently associated with a different marketer. Similar naming does not establish the same composition or company relationship.

Ajanta is independently documented as a manufacturer of generic tadalafil in another regulated market, but that fact should not be substituted for product-specific evidence about Indian Tadafil manufacturing. Brand name, company role and regulatory status must all be verified for the exact product and jurisdiction.